Cybin Inc. filings document Helus Pharma's status as a foreign issuer reporting current events through Form 6-K materials and related exhibits. The filings include company news releases covering the HLP003 and HLP004 clinical programs, regulatory designations, clinical research collaborations, scientific advisory matters, and management changes.
The company's regulatory record also covers capital-structure disclosure, shareholder voting matters, governance matters, clinical or regulatory disclosures, operating and financial results, and risk-oriented cautionary statements associated with its clinical-stage pharmaceutical business.
Helus Pharma, the commercial name of Cybin Inc., reported audited fiscal 2026 results and key pipeline progress. Cash totaled $157.3 million as of March 31, 2026, and the company recently completed a $50 million underwritten offering to support its late-stage programs.
The net loss widened to $148.0 million for the year, driven by higher cash-based operating expenses of $131.7 million as Phase 3 trials for HLP003 and Phase 2 work on HLP004 advanced. The Phase 3 APPROACH study of HLP003 in Major Depressive Disorder has surpassed 88% enrollment, with topline data targeted for Q4 2026, while enrollment is underway in the EMBRACE pivotal study and rollover into the EXTEND durability study continues.
In anxiety, HLP004 delivered a statistically significant ~10‑point improvement on the HAM-A scale at six weeks in a Phase 2 signal detection study, with durable effects to at least six months. Helus is also progressing HLP005 toward candidate selection in the second half of 2027, has added multiple high-profile R&D and medical leaders, and notes supportive U.S. policy signals for psychedelic therapies, including recognition in a White House press release.
Cybin Inc. filed its Annual Report on Form 40-F for the fiscal year ended March 31, 2026, reporting 51,631,804 common shares outstanding as of March 31, 2026. The report attaches the AIF, audited consolidated financial statements, and the MD&A as Exhibits 99.1–99.3. Management concluded that disclosure controls and internal control over financial reporting were effective as of March 31, 2026. The company confirms foreign private issuer status, lists its common shares on Nasdaq under the symbol HELP, and notes it is an emerging growth company.
Helus Pharma, the commercial name of Cybin Inc., has closed an underwritten offering of 10,309,280 common shares at US$4.85 per share for aggregate gross proceeds of US$50 million. Cantor and Barclays acted as joint bookrunning managers, with Bloom Burton Securities Inc. and Lucid Capital Markets as lead managers.
The company plans to use the net proceeds to advance HLP003 for major depressive disorder, HLP004 for generalized anxiety disorder, and HLP005, as well as for working capital and general corporate purposes. Phase 3 APPROACH data for HLP003 are expected in the fourth quarter of 2026.
Helus Pharma, the commercial name of Cybin Inc., has priced a US$50 million underwritten equity financing and reported strong progress in its lead depression program. The company is selling 10,309,280 common shares at US$4.85 each in a fully underwritten offering, with Cantor and Barclays as joint bookrunners. Helus plans to use the proceeds mainly to advance HLP003, its Phase 3 serotonergic agonist for major depressive disorder, as well as HLP004 for generalized anxiety disorder, HLP005 and general corporate purposes. Separately, the APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder has surpassed 86% enrollment, with topline data targeted for the fourth quarter of 2026. Prior Phase 2 data for HLP003 showed a ~23‑point improvement on the Montgomery‑Åsberg Depression Rating Scale at 12 months after two 16 mg doses, with response and remission rates improving over time.
Cybin Inc., operating commercially as Helus Pharma, filed a Form 6-K highlighting Helus Pharma’s participation in the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on June 15-16, 2026, where its Chief Medical Officer will join a fireside chat available on demand.
The filing also describes Helus Pharma as a clinical-stage company developing proprietary novel serotonergic agonists (NSAs) for mental health conditions, including HLP003 in Phase 3 for adjunctive treatment of major depressive disorder with U.S. FDA Breakthrough Therapy Designation and HLP004 in Phase 2 for generalized anxiety disorder, alongside an expanded NSA research portfolio and standard forward-looking statement cautions.
Cybin Inc., operating as Helus Pharma, furnished a report noting that Interim CEO Eric So will join a fireside chat at the Jefferies Global Healthcare Conference in New York, held June 2–4, 2026. The session will be webcast live on June 4, 2026, at 2:35 p.m. EDT, with a replay available on the company’s investor relations site.
Helus Pharma is described as a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs) aimed at improving treatments for depression, anxiety and other mental health conditions. Its lead NSA, HLP003, is in Phase 3 clinical development for adjunctive treatment of major depressive disorder and has U.S. FDA Breakthrough Therapy Designation, while HLP004 is in Phase 2 for generalized anxiety disorder. The release includes extensive forward-looking statement cautions and emphasizes that none of the company’s programs have yet been approved by regulators.
Cybin Inc. Schedule 13G/A Amendment No. 3 reports that Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen beneficially own 686,669 Common Shares of Cybin Inc., representing 1.4% of the class as of the close of business on March 31, 2026. The disclosure states this amount includes 666,985 Common Shares issuable upon exercise of warrants. The filing attributes shared voting and dispositive power of 686,669 shares to the reporting persons and notes Point72 entities hold these interests through an investment fund they manage.
CYBIN INC. reports that Sirenia Capital Management LP and Alex Silverstein together beneficially hold 3,677,966 Common Shares, representing 7.2% of the class when assuming exercise of related warrants. The filing states 50,035,795 Common Shares outstanding as of February 12, 2026 and notes that the reported position includes 969,500 shares issuable upon exercise of warrants.
The statement is a Schedule 13G disclosure of ownership by an institutional investor and its managing member and quantifies shared voting and dispositive power. The percentage is calculated on the cited outstanding share base and is presented with the exercise assumption specified in the filing.
Cybin Inc., operating as Helus Pharma, furnished a Form 6-K highlighting a new collaboration between Helus Pharma and TARA Mind to support recruitment for the HLP003 Phase 3 program in Major Depressive Disorder, which has FDA Breakthrough Therapy Designation.
The partnership focuses on outreach to veteran communities, aligning with a recent U.S. Executive Order that promotes access to innovative mental health treatments for high‑risk groups such as veterans. TARA Mind will use its veteran-focused networks and collaborative care platform to expand awareness of clinical research opportunities and mental health resources.
The filing also reiterates that Helus Pharma is a clinical-stage company developing proprietary novel serotonergic agonists (NSAs), including HLP003 for adjunctive treatment of major depressive disorder and HLP004 in Phase 2 for generalized anxiety disorder, supported by a broader research portfolio across several countries.
Cybin Inc., operating commercially as Helus Pharma, filed a Form 6-K to share a news release about an upcoming conference appearance and to describe its clinical pipeline. Interim CEO Eric So will speak on a Milken Institute Global Conference panel titled “The Next Wave of Health Innovation” on May 4, 2026, with a live and archived webcast available on the company’s investor relations site.
Helus Pharma is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs) aimed at improving treatments for depression, anxiety and other mental health conditions. Lead candidate HLP003 is in Phase 3 development for adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, while HLP004 is in Phase 2 for generalized anxiety disorder. The release includes extensive cautionary language, emphasizing that NSAs and the company’s product candidates have not been approved by regulators, their efficacy has not been confirmed, and further clinical research and regulatory approvals are required.